Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.22Last Year’s EPS
-$1.38Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -11.95%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress, particularly with the NDA submissions for aficamten and positive clinical data. Commercial preparations are well underway, backed by a strong financial position. However, increased losses and low revenues remain challenges.Company Guidance
During Cytokinetics' Q3 2024 earnings call, the company provided detailed guidance and updates on their pipeline, focusing heavily on the progress with aficamten. The company completed the rolling submission for aficamten's new drug application (NDA) with the FDA and is anticipating a priority review, though they expect a standard review as a base case. They are preparing for commercial launch in the U.S. with prelaunch activities, including a healthcare professional awareness campaign. Financially, Cytokinetics reported a net loss of $160.5 million for the quarter, with cash and investments totaling approximately $1.3 billion. Despite the loss, they maintained their financial guidance for the year. Upcoming milestones include furthering clinical trials such as MAPLE-HCM, and the initiation of new trials, including COMET-HF for omecamtiv mecarbil and AMBER-HFpEF for CK-586.New Drug Application Submitted for Aficamten
Cytokinetics completed the rolling submission and submitted the NDA for aficamten to the FDA for obstructive HCM, marking a significant milestone.
Aficamten NDA Accepted in China
The NDA for aficamten was accepted for filing in China, expanding its potential global reach.
Positive Data from SEQUOIA-HCM
The SEQUOIA-HCM study showed aficamten led to improvements in cardiac structure and function, suggesting potential disease-modifying effects.
Commercial Preparedness for Aficamten
Cytokinetics undertook significant commercial readiness activities for aficamten, including disease awareness campaigns and sales force preparation.
Strong Financial Position
Cytokinetics ended the quarter with approximately $1.3 billion in cash, cash equivalents, and investments.
---
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $55.50 | $55.84 | +0.61% |
| Aug 08, 2024 | $54.00 | $55.79 | +3.31% |
| May 08, 2024 | $65.27 | $64.02 | -1.92% |
| Feb 27, 2024 | $80.99 | $73.09 | -9.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2024 (Q4) is -$1.22.
---